DARE (Dare Bioscience) EBIT: $-11.97 Mil (TTM As of Mar. 2026)


DARE Dare Bioscience Inc DARE
23 GF Score
Price $2.00
! 4 Warning Signs
View Full Analysis

What is Dare Bioscience EBIT?

Dare Bioscience DARE -3.85% 23 EBIT is $-11.97 Mil as of Mar. 2026. GuruFocus rates DARE with a GF Score™ of 23/100. The stock has 4 warning signs investors should review.

Dare Bioscience's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was $-3.00 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was $-11.97 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Dare Bioscience's annualized ROC % for the quarter that ended in Mar. 2026 was -45.52%. Dare Bioscience's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -295.18%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Dare Bioscience's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -91.70%.

Dare Bioscience  (NAS:DARE) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Dare Bioscience's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-11.996 * ( 1 - 0% )/( (27.181 + 25.528)/ 2 )
=-11.996/26.3545
=-45.52 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=32.475 - 1.916 - ( 24.711 - max(0, 23.686 - 27.064+24.711))
=27.181

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=27.828 - 1.76 - ( 18.52 - max(0, 21.119 - 21.659+18.52))
=25.528

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Dare Bioscience's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-11.996/( ( (4.401 + max(-19.809, 0)) + (3.727 + max(-17.472, 0)) )/ 2 )
=-11.996/( ( 4.401 + 3.727 )/ 2 )
=-11.996/4.064
=-295.18 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 1.78) - (1.916 + 19.651 + 0.021999999999998)
=-19.809

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 2.451) - (1.76 + 18.15 + 0.013000000000002)
=-17.472

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Dare Bioscience's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-11.97/13.054
=-91.70 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dare Bioscience EBIT Related Terms

Dare Bioscience EBIT Historical Data

* Premium members only.

The historical data trend for Dare Bioscience's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dare Bioscience EBIT Chart

Dare Bioscience Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -39.07 -31.39 -30.94 -23.45 -13.55

Dare Bioscience Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.58 -3.83 -3.67 -1.47 -3.00

DARE vs TVGN, LITS, BOLD: EBIT Comparison

For the Biotechnology subindustry, Dare Bioscience's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Dare Bioscience EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dare Bioscience's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Dare Bioscience's EV-to-EBIT falls into.


DARE
23GF Score
Dare Bioscience Inc DARE
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Dare Bioscience EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-11.97 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-11.97 Mil mean?
Dare Bioscience (DARE) has a EBIT of $-11.97 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Dare Bioscience.
Is Dare Bioscience's EBIT too high?
Dare Bioscience's current EBIT is $-11.97 Mil. Overall, Dare Bioscience has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Dare Bioscience's EBIT compare to TVGN and LITS?
Dare Bioscience's EBIT of $-11.97 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Dare Bioscience. Dare Bioscience's current EBIT is $-11.97 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dare Bioscience stock overvalued right now?
Dare Bioscience (DARE) has a current EBIT of $-11.97 Mil. The current EBIT is $-11.97 Mil. Dare Bioscience's overall GF Score™ is 23/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Dare Bioscience (DARE), the current EBIT is $-11.97 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Dare Bioscience Business Description

Address 3655 Nobel Drive, Suite 260, San Diego, CA, USA, 92122
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.
23GF Score

Get the complete analysis for DARE

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.00
Price